ArticleEuropean urology open science2026
Ex Vivo Microtumor Testing to Predict Chemotherapy Responses in Patients with Bladder Cancer.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with bladder cancer (BC) may receive intravesical or systemic chemotherapy, but predictive biomarkers to guide treatment selection are lacking. Consequently, some patients receive ineffective treatment, resulting in unnecessary toxicity and an increased risk of tumor progression. Objective: To evaluate the feasibility of ex vivo micro-tumor testing for predicting chemotherapy response in patients with BC. Design setting and participants: In this prospective study, 65 patients with BC were enrolled (Institutional Review Board no. MEC-2022-0233). Tumor samples were collected during transurethral resection or radical cystectomy. BC was confirmed by uropathological review, supported by the detection of BC-associated mutations in hTERT, FGFR3, and PIK3CA. Patient-derived micro-tumors were exposed ex vivo to anticancer drugs, and responses were assessed using image-based measurements of viability and morphology. Outcome measurements and statistical analysis: The primary outcome was successful completion of ex vivo drug testing within 14 days of tissue collection. The secondary outcome was concordance between ex vivo sensitivity and clinical response to platinum-based chemotherapy. Clinical response data were available for nine patients. Results and limitations: Ex vivo drug testing was successful for 48 of 65 patients (74%), with all successful results generated within 14 days of tissue collection. Among the nine patients with evaluable clinical outcomes following platinum-based chemotherapy, ex vivo responses corresponded with observed treatment responses. The main limitations were the small clinical correlation cohort and the limited number of drugs evaluated. Conclusions: Ex vivo micro-tumor drug testing is feasible for BC within a clinically relevant timeframe. The observed correspondence between ex vivo and clinical responses to platinum-based chemotherapy supports further investigation of this approach for personalized treatment selection in BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.